Lenalidomide Aurobindo

Lenalidomide, the active ingredient in Lenalidomide Aurobindo, is an immunomodulatory drug presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patient populations.

GNH USA supplies Lenalidomide Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.

Multiple Myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission in eligible patients. Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases when combined with other agents.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause bruising. - Anemia: decreased red blood cell count leading to weakness. - Diarrhea: loose stools that can affect hydration. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression with fever. - Serious infections: opportunistic or bacterial infections requiring hospitalization. - Secondary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances. - Hypersensitivity reactions: anaphylaxis or severe skin reactions.

Lenalidomide requires careful monitoring and specific safety measures.

Pregnancy: contraindicated; drug is teratogenic (Category X). Blood counts: monitor complete blood count regularly during therapy. Thromboembolic risk: assess patient history and consider prophylactic anticoagulation. Renal function: evaluate and adjust use in patients with impaired kidney function. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep in original container, protect from moisture and light.

Lenalidomide can interact with several medication classes, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Live vaccines: risk of uncontrolled infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce therapeutic effectiveness. - Immunosuppressants: increased susceptibility to infections. - NSAIDs: potential additive effect on platelet function.